Dr. Jason Rich, M.D.
Claim this profileWashington University School of Medicine
Studies Squamous Cell Carcinoma
Studies Neck Cancer
6 reported clinical trials
11 drugs studied
Area of expertise
1Squamous Cell Carcinoma
Stage III
p16 positive
p16 negative
2Neck Cancer
Stage III
HPV negative
Stage IV
Affiliated Hospitals
Clinical Trials Jason Rich, M.D. is currently running
Chemotherapy and Radiation
for Cutaneous Angiosarcoma
Angiosarcoma is a rare and aggressive form of soft tissue sarcoma. Prior work demonstrates very poor outcomes, with most patients developing metastatic disease and less than 50% surviving greater than 5 years. In other soft tissue sarcomas, the use of radiotherapy and/or chemotherapy have improved progression-free survival in patients undergoing limited, organ-sparing surgeries. Taxane chemotherapy has shown efficacy in patients with metastatic angiosarcoma, but this has not been tested in patients with localized disease. This study examines the efficacy of induction paclitaxel followed by concurrent chemoradiation therapy with paclitaxel prior to curative surgical resection.
Recruiting1 award Phase 1 & 27 criteria
Radiation, Cisplatin, and Surgery
for Throat Cancer
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\>90%) are caused by the human papillomavirus (HPV) and are often cured with current therapy. However, patients treated with surgery followed by postoperative adjuvant chemotherapy and radiation therapy (POA(C)RT) still experience substantial morbidity. In this highly curable disease, current clinical research interest is focused on investigation of de-escalated therapy, with the goal to reduce treatment-related adverse events (AEs) while maintaining a low recurrence rate. In this study, patients with HPV-related OPSCC will undergo resection of the primary tumor site and involved/at-risk regional neck nodes. Based on the pathology report, patients will be assigned to: * Arm 1 (de-POACRT-42 Gy) * Arm 2A (de-POART-42 Gy) * Arm 2B (de-POART-37.8 Gy) * Arm 2C (de-POACRT-30 Gy). All patients with high-risk pathology will be assigned to Arm 1 whereas patients with intermediate-risk pathology will be randomized (1:1:1) to Arm 2A, Arm 2B, or Arm 2C. Patients with highest-risk pathology and low-risk pathology will be removed from the trial after surgery and will be advised to pursue standard of care options.
Recruiting1 award Phase 26 criteria
More about Jason Rich, M.D.
Clinical Trial Related7 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jason Rich, M.D. has experience with
- Cisplatin
- Radiation Therapy
- CareOrbit
- Cetuximab
- Intensity-Modulated Radiation Therapy
- Palbociclib
Breakdown of trials Jason Rich, M.D. has run
Squamous Cell Carcinoma
Neck Cancer
Head and Neck Cancers
Head and Neck Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jason Rich, M.D. specialize in?
Jason Rich, M.D. focuses on Squamous Cell Carcinoma and Neck Cancer. In particular, much of their work with Squamous Cell Carcinoma has involved Stage III patients, or patients who are p16 positive.
Is Jason Rich, M.D. currently recruiting for clinical trials?
Yes, Jason Rich, M.D. is currently recruiting for 3 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Jason Rich, M.D. has studied deeply?
Yes, Jason Rich, M.D. has studied treatments such as Cisplatin, Radiation therapy, CareOrbit.
What is the best way to schedule an appointment with Jason Rich, M.D.?
Apply for one of the trials that Jason Rich, M.D. is conducting.
What is the office address of Jason Rich, M.D.?
The office of Jason Rich, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.